Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function

Patsaoura, Aikaterini; Tatsi, Elizabeth‐Barbara; Margeli, Alexandra; Kanavaki, Ino; Delaporta, Polyxeni; Kyriakopoulou, Dimitra; Kouraklis-Symeonidis, Alexandra; Kattamis, Antonios; Papassotiriou, Ioannis

doi:10.1016/j.clinbiochem.2014.03.017

Cited by 20 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adiponectin serum levels are, however, not correlated with LCN2 in any of the cohorts analyzed herein. A main function of LCN2 is the sequestering of iron [16] but serum levels do not correlate with measures of iron homeostasis in line with published observations [38].…”

Section: Discussionsupporting

confidence: 80%

Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis

et al. 2016

View full text Add to dashboard Cite

“…It should be noted that the concentrations of Lcn2 used in this in vitro study (1-5 µg/ml) were approximately 1-2 orders of magnitude higher than the plasma levels found in clinical studies in thalassemia patients (Patsaoura et al, 2014;Roudkenar et al, 2008;Xu et al, 2012). Therefore, influences of Lcn2 on the pathophysiology of thalassemia-associated iron overload cardiomyopathy may be different from the findings of this study.…”

Section: Lcn2 Affects Inflammation Iron Accumulation and Apoptosicontrasting

confidence: 74%

Roles of lipocalin 2 and adiponectin in iron overload cardiomyopathy

Siri‐Angkul

Chattipakorn

2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Thalassemia is among the most common genetic diseases worldwide. Ineffective erythropoiesis, chronic hemolysis, and regular blood transfusion in thalassemia patients lead to increased iron burden. Iron overload cardiomyopathy is the most severe co-morbidity and most common cause of mortality in thalassemia patients. Although its associated mechanisms are still not completely understood, cellular iron mishandling, chronic inflammation, and oxidative stress appear to be the key processes involved. In order to acquire a more comprehensive insight of the impact of cardiac iron overload, these alterations need to be intensively investigated. This comprehensive mini-review focuses on two emergent molecules which have been shown to potentially play significant roles in iron overload cardiomyopathy. These two molecules are an iron-transporting protein, lipocalin 2, and an anti-inflammatory adipokine, adiponectin. Reports from in vitro and in vivo studies are comprehensively summarized. Clinical studies examining the roles of these molecules in thalassemia patients are also presented and discussed.

show abstract

“…There is evidence in the literature of a significant correlation between the severity of anemia and markers of tubular abnormalities in patients with β-TM. The underlying pathophysiological mechanism is considered multifactorial, including increased vascular resistance, with consequent hyperdynamic circulation and modulation of the renal plasma flow and GFR [31,32].…”

Section: Discussionmentioning

confidence: 99%

Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy

Capolongo

Zacchia

Beneduci

et al. 2020

Kidney Blood Press Res

View full text Add to dashboard Cite

Introduction: Renal dysfunction is a frequent complication in patients suffering from β-thalassemia major (β-TM). The aim of this study was to analyze the renal function and urine metabolomic profile of β-TM patients undergoing transfusions and deferasirox (DFX) therapy, in order to better characterize and shed light on the pathogenesis of renal disease in this setting. Methods and Subjects: 40 patients affected by β-TM treated with DFX and 35 age-and gender-matched healthy controls were enrolled in the study. Renal function was assessed. Glomerular filtration rate (GFR) was estimated with CKD-EPI and Schwartz formula for adults and children, respectively. Renal tubular function and maximal urine concentration ability were tested. Urine specimens were analyzed by nuclear magnetic resonance spectroscopy to identify the urinary metabolite profiles. Results: The study of renal function in β-TM patients revealed normal estimated (e)GFR mean values and the albumin-to-creatinine ratio was < 30 mg/g. The analysis of tubular function showed normal basal plasma electrolyte levels; 60% of patients presented hypercalciuria and many subjects showed defective urine concentration. Several amino acids, N-methyl compounds, and organic acids were overexcreted in the urine of thalassemic patients compared with controls. Discussion: The major finding of this work is that β-TM patients and controls exhibit different concentrations of some metabolites in the urine. Early recognition of urinary abnormalities may be useful to detect and prevent kidney damage.

show abstract

Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function

Cited by 20 publications

References 19 publications

Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis

Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis

Roles of lipocalin 2 and adiponectin in iron overload cardiomyopathy

Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy

Contact Info

Product

Resources

About